Abstract
The mammalian tachykinin (TK) peptides and their three neurokinin (NK) receptors represent an effector system with wide-ranging actions on neuronal, airway smooth muscle, mucosal, endothelial, immune, inflammatory and remodeling cell function. Recent clinical and preclinical data suggests pathophysiological relevance for TKs in various diseases including asthma, emesis and depression. The promiscuous TK-NK receptor interactions and incompletely overlapping functions mediated by each NK receptor may indicate added therapeutic benefit of using multiple NK receptor blockade. Consequently, there has been substantial pharmaceutical effort in projects to develop nonpeptide dual and triple NK receptor antagonists. This review identifies the chemical and biological approach used to develop a TK antagonist active at the three NK receptors. Clinical activity has been observed using single and / or dual NK receptor antagonists in asthma, depression / anxiety and, most notably, emesis trials but no compound with mono or multiple NK receptor antagonist activities has cleared all the development and regulatory hurdles to commercialization. Current experience indicates that potent dual and triple NK receptor-selective antagonists possessing appropriate affinity and pharmacokinetic properties can be developed. As an example, the biological and pharmacokinetic profiles of a new representative of this class of agent, SCH 206272, is detailed in the present review. Whether such agents will fulfill researchers expectations must await further clinical trials.
Keywords: nk receptor antagonists, mammalian tachykinin, neurokinin (nk) receptors, tk-nk receptor interactions, nk receptors, sch 206272
Current Topics in Medicinal Chemistry
Title: Development and Potential Utility of Dual and Triple NK Receptor Antagonists
Volume: 3 Issue: 12
Author(s): Charles A. Rizzo, John C. Anthes, Michel R. Corboz, Richard W. Chapman, Neng-Yang Shih, Greg A. Reichard, Kwokei J. Ng and John A. Hey
Affiliation:
Keywords: nk receptor antagonists, mammalian tachykinin, neurokinin (nk) receptors, tk-nk receptor interactions, nk receptors, sch 206272
Abstract: The mammalian tachykinin (TK) peptides and their three neurokinin (NK) receptors represent an effector system with wide-ranging actions on neuronal, airway smooth muscle, mucosal, endothelial, immune, inflammatory and remodeling cell function. Recent clinical and preclinical data suggests pathophysiological relevance for TKs in various diseases including asthma, emesis and depression. The promiscuous TK-NK receptor interactions and incompletely overlapping functions mediated by each NK receptor may indicate added therapeutic benefit of using multiple NK receptor blockade. Consequently, there has been substantial pharmaceutical effort in projects to develop nonpeptide dual and triple NK receptor antagonists. This review identifies the chemical and biological approach used to develop a TK antagonist active at the three NK receptors. Clinical activity has been observed using single and / or dual NK receptor antagonists in asthma, depression / anxiety and, most notably, emesis trials but no compound with mono or multiple NK receptor antagonist activities has cleared all the development and regulatory hurdles to commercialization. Current experience indicates that potent dual and triple NK receptor-selective antagonists possessing appropriate affinity and pharmacokinetic properties can be developed. As an example, the biological and pharmacokinetic profiles of a new representative of this class of agent, SCH 206272, is detailed in the present review. Whether such agents will fulfill researchers expectations must await further clinical trials.
Export Options
About this article
Cite this article as:
Rizzo A. Charles, Anthes C. John, Corboz R. Michel, Chapman W. Richard, Shih Neng-Yang, Reichard A. Greg, Ng J. Kwokei and Hey A. John, Development and Potential Utility of Dual and Triple NK Receptor Antagonists, Current Topics in Medicinal Chemistry 2003; 3 (12) . https://dx.doi.org/10.2174/1568026033451844
DOI https://dx.doi.org/10.2174/1568026033451844 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allopurinol and Loss of Consciousness in a 78-old Year Man Suffering from Gout
Infectious Disorders - Drug Targets Computer Prediction of Cardiovascular and Hematological Agents by Statistical Learning Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Current Medicinal Chemistry Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design Stereoselectivity in Drug Metabolism: Molecular Mechanisms and Analytical Methods
Current Drug Metabolism Functional Food with Some Health Benefits, So Called Superfood: A Review
Current Nutrition & Food Science Globalization of Clinical Trials – Where are We Heading?
Current Clinical Pharmacology Dual Acting Antihistaminergic Agents
Mini-Reviews in Medicinal Chemistry Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) How to Prevent Postpartum Relapse to Smoking
Current Pediatric Reviews Interaction of Small Molecules with Specific Immune Receptors: The p-i Concept and its Consequences
Current Immunology Reviews (Discontinued) Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Extracellular Matrix, Integrins, and Mesenchymal Cell Function in the Airways
Current Drug Targets Purification and Biological Evaluation of Some Bioactive Metabolomics as Antimicrobial Agent
Letters in Drug Design & Discovery Neutrophil Derived Microvesicles: Emerging Role of a Key Mediator to the Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Myocardial Protection Against Ischemia-Reperfusion Injury: Novel Approaches in Maintaining Homeostatic Stability in Blood
Recent Patents on Cardiovascular Drug Discovery Identification and Treatment of Patients with Early COPD
Current Respiratory Medicine Reviews Current Applications of Therapeutic Gases in Neonatal Intensive Care
Current Pediatric Reviews Transgenic Models in Allergic Responses
Current Drug Targets